Viewpoints

Latest

17 Nov 2020

Drug-resistant Infections: The Silent Pandemic We Must Tackle Now

The unchecked growth of drug-resistant infections is a silent pandemic with long-term implications for global health security. As the world reels from the impact of COVID-19, it would be a tragedy not to apply the lessons we are learning to the fight against drug resistance.

Why are new antibacterials failing as commercial products? – by Patricia A. Bradford

COVID-19: Coinfection, secondary bacterial infections and AMR in India – by Venkatasubramanian Ramasubramanian

Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic – by Markus Heep, Esther Bettiol, Tanyaporn Wansom and Hilary Johnstone

A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need – by John Rex

Why we need a new access model for antibiotics – by Yann Ferrisse and Fernando Pascual Martinez

Moving from paper to action – The status of National AMR Action Plans in African countries – by Mirfin Mpundu

Cookie Policy

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.